Key result
Implantation of the PROLIM biodegradable-polymer sirolimus-eluting stent resulted in a 5% rate of the primary composite safety endpoint (cardiac death or non-fatal MI) at 12 months.
Population
100 consecutive patients with de novo coronary artery lesions treated with percutaneous coronary…
Design
Cohort
Follow-up
12 months
Authors
Loading...
Registry data indicate acceptable short-term safety for PROLIM stent; hypothesis-generating and leaves open need for randomized comparisons.
Observational (n=100)
No
The biodegradable-polymer sirolimus-eluting PROLIM stent demonstrated acceptable safety and efficacy at 12 months in a small prospective registry of patients with de novo coronary lesions.
Roleder et al. (2015) conducted an observational in coronary artery disease (n=100). PROLIM biodegradable polymer sirolimus-eluting stent was evaluated on composite safety (cardiac death, non-fatal myocardial infarction). Implantation of the PROLIM biodegradable-polymer sirolimus-eluting stent resulted in a 5% rate of the primary composite safety endpoint (cardiac death or non-fatal MI) at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: